antisense drug


Also found in: Dictionary, Thesaurus, Medical.

antisense drug

[‚an·tē¦sens ′drəg]
(medicine)
A gene-based drug containing material that inhibits the synthesis of abnormal protein (which is typically caused by a specific disease state) by specifically binding to the ribonucleic acid responsible for its formation.
Mentioned in ?
References in periodicals archive ?
In this collaboration, Ionis will be responsible for the identification of antisense drug candidates based on selected targets, while Biogen will be responsible for and pay for non-clinical studies, clinical development, manufacturing, and commercialization.
We believe that this work is the foundation for a robust drug discovery platform that takes advantage of using single-stranded RNA-like antisense drugs that harness the power of the RNAi pathway.
Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
"The Crooke patents are a product of our pioneering efforts to investigate and understand the mechanisms by which antisense drugs work and to create attractive antisense drugs that exploit those mechanisms.
The 28 chapters are divided into sections on introducing antisense drug action, the basics of oligonucleotide-based therapeutics, hybridization-based drugs, other chemical classes, and applications.
Lilly has several antisense drug candidates derived from the collaboration that are in or approaching clinical trials.
Antisense drugs send little chunks of man-made DNA into the body that target and disable specific disease-causing genes, like little smart bombs.
At the Teratology Society's annual meeting held in June at Las Croabas, Puerto Rico, Ecker reported preliminary results from a human test of an antisense drug aimed at cytomegalovirus (CMV), a type of herpesvirus that can cause a vision-threatening eye infection for AIDS patients.
In conjunction, Ionis said it is responsible for the identification of antisense drug candidates based on selected targets, while Biogen will have the option to license therapies and will be responsible for and pay for non-clinical studies, clinical development, manufacturing and commercialisation.
Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
ISIS-TTRRx is an antisense drug the companies are developing for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.